Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study

Abstract We investigated magnetic resonance imaging (MRI) criteria identifying residual tumours in patients with triple-negative and human epidermal growth factor receptor type 2-positive (HER2+) breast cancer following neoadjuvant chemotherapy. Retrospectively, 290 patients were included who had un...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yunju Kim, Sung Hoon Sim, Boram Park, In Hye Chae, Jai Hong Han, So-Youn Jung, Seeyoun Lee, Youngmi Kwon, In Hae Park, Kyounglan Ko, Chan Wha Lee, Keun Seok Lee, Han-Sung Kang, Eun Sook Lee
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e9e8380a776043ca99b512895ec1127e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e9e8380a776043ca99b512895ec1127e
record_format	dspace
spelling	oai:doaj.org-article:e9e8380a776043ca99b512895ec1127e2021-12-02T14:01:37ZCriteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study10.1038/s41598-020-79743-82045-2322https://doaj.org/article/e9e8380a776043ca99b512895ec1127e2021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-79743-8https://doaj.org/toc/2045-2322Abstract We investigated magnetic resonance imaging (MRI) criteria identifying residual tumours in patients with triple-negative and human epidermal growth factor receptor type 2-positive (HER2+) breast cancer following neoadjuvant chemotherapy. Retrospectively, 290 patients were included who had undergone neoadjuvant chemotherapy and definitive surgery. Clinicopathological features, as well as lesion size and lesion-to-background parenchymal signal enhancement ratio (SER) in early- and late-phase MRIs, were analysed. Receiver operating characteristic (ROC) analyses evaluated diagnostic performances. Maximal MRI values showing over 90% sensitivity and negative predictive value (NPV) were set as cut-off points. Identified MRI criteria were prospectively applied to 13 patients with hormone receptor-negative (HR-) tumours. The lesion size in HR-HER2-tumours had the highest area under the ROC curve value (0.92), whereas this parameter in HR + HER2 + tumours was generally low (≤ 0.75). For HR-tumours, both sensitivity and NPV exceeded the 90% threshold for early size > 0.2 cm (HR-HER2-) or > 0.1 cm (HR-HER2 +), late size > 0.4 cm, and early SER > 1.3. In the prospective pilot cohort, the criteria size and early SER did not find false negative cases, but one case was false negative with late SER. Distinguishing residual tumours based on MRI is feasible in selected triple-negative and HER2 + breast cancer patients.Yunju KimSung Hoon SimBoram ParkIn Hye ChaeJai Hong HanSo-Youn JungSeeyoun LeeYoungmi KwonIn Hae ParkKyounglan KoChan Wha LeeKeun Seok LeeHan-Sung KangEun Sook LeeNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yunju Kim Sung Hoon Sim Boram Park In Hye Chae Jai Hong Han So-Youn Jung Seeyoun Lee Youngmi Kwon In Hae Park Kyounglan Ko Chan Wha Lee Keun Seok Lee Han-Sung Kang Eun Sook Lee Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study
description	Abstract We investigated magnetic resonance imaging (MRI) criteria identifying residual tumours in patients with triple-negative and human epidermal growth factor receptor type 2-positive (HER2+) breast cancer following neoadjuvant chemotherapy. Retrospectively, 290 patients were included who had undergone neoadjuvant chemotherapy and definitive surgery. Clinicopathological features, as well as lesion size and lesion-to-background parenchymal signal enhancement ratio (SER) in early- and late-phase MRIs, were analysed. Receiver operating characteristic (ROC) analyses evaluated diagnostic performances. Maximal MRI values showing over 90% sensitivity and negative predictive value (NPV) were set as cut-off points. Identified MRI criteria were prospectively applied to 13 patients with hormone receptor-negative (HR-) tumours. The lesion size in HR-HER2-tumours had the highest area under the ROC curve value (0.92), whereas this parameter in HR + HER2 + tumours was generally low (≤ 0.75). For HR-tumours, both sensitivity and NPV exceeded the 90% threshold for early size > 0.2 cm (HR-HER2-) or > 0.1 cm (HR-HER2 +), late size > 0.4 cm, and early SER > 1.3. In the prospective pilot cohort, the criteria size and early SER did not find false negative cases, but one case was false negative with late SER. Distinguishing residual tumours based on MRI is feasible in selected triple-negative and HER2 + breast cancer patients.
format	article
author	Yunju Kim Sung Hoon Sim Boram Park In Hye Chae Jai Hong Han So-Youn Jung Seeyoun Lee Youngmi Kwon In Hae Park Kyounglan Ko Chan Wha Lee Keun Seok Lee Han-Sung Kang Eun Sook Lee
author_facet	Yunju Kim Sung Hoon Sim Boram Park In Hye Chae Jai Hong Han So-Youn Jung Seeyoun Lee Youngmi Kwon In Hae Park Kyounglan Ko Chan Wha Lee Keun Seok Lee Han-Sung Kang Eun Sook Lee
author_sort	Yunju Kim
title	Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study
title_short	Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study
title_full	Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study
title_fullStr	Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study
title_full_unstemmed	Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study
title_sort	criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/e9e8380a776043ca99b512895ec1127e
work_keys_str_mv	AT yunjukim criteriaforidentifyingresidualtumoursafterneoadjuvantchemotherapyofbreastcancersamagneticresonanceimagingstudy AT sunghoonsim criteriaforidentifyingresidualtumoursafterneoadjuvantchemotherapyofbreastcancersamagneticresonanceimagingstudy AT borampark criteriaforidentifyingresidualtumoursafterneoadjuvantchemotherapyofbreastcancersamagneticresonanceimagingstudy AT inhyechae criteriaforidentifyingresidualtumoursafterneoadjuvantchemotherapyofbreastcancersamagneticresonanceimagingstudy AT jaihonghan criteriaforidentifyingresidualtumoursafterneoadjuvantchemotherapyofbreastcancersamagneticresonanceimagingstudy AT soyounjung criteriaforidentifyingresidualtumoursafterneoadjuvantchemotherapyofbreastcancersamagneticresonanceimagingstudy AT seeyounlee criteriaforidentifyingresidualtumoursafterneoadjuvantchemotherapyofbreastcancersamagneticresonanceimagingstudy AT youngmikwon criteriaforidentifyingresidualtumoursafterneoadjuvantchemotherapyofbreastcancersamagneticresonanceimagingstudy AT inhaepark criteriaforidentifyingresidualtumoursafterneoadjuvantchemotherapyofbreastcancersamagneticresonanceimagingstudy AT kyounglanko criteriaforidentifyingresidualtumoursafterneoadjuvantchemotherapyofbreastcancersamagneticresonanceimagingstudy AT chanwhalee criteriaforidentifyingresidualtumoursafterneoadjuvantchemotherapyofbreastcancersamagneticresonanceimagingstudy AT keunseoklee criteriaforidentifyingresidualtumoursafterneoadjuvantchemotherapyofbreastcancersamagneticresonanceimagingstudy AT hansungkang criteriaforidentifyingresidualtumoursafterneoadjuvantchemotherapyofbreastcancersamagneticresonanceimagingstudy AT eunsooklee criteriaforidentifyingresidualtumoursafterneoadjuvantchemotherapyofbreastcancersamagneticresonanceimagingstudy
_version_	1718392176362127360

Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study

Ejemplares similares